Molecular-targeted therapies for ovarian cancer: Prospects for the future

International Journal of Clinical Oncology

Volumn 17, Issue 5, 2012, Pages 424-429

  Sudo, Tamotsu ^a  

^a HYOGO CANCER CENTER   (Japan)

Author keywords

Angiogenesis; BRCA; MAPK; Ovarian cancer; PI3K mTOR

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CRIZOTINIB; DNA; ERLOTINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; RAF PROTEIN; RAS PROTEIN; SELUMETINIB; TRASTUZUMAB; TUMOR MARKER; VASCULAR TARGETING AGENT;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CARCINOGENESIS; CIRCULATING TUMOR CELL; CYTOREDUCTIVE SURGERY; DNA REPAIR; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; EARLY DIAGNOSIS; GENE MUTATION; HUMAN; LAPAROTOMY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MICROSATELLITE INSTABILITY; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; OVARY CANCER; PERITONEUM CANCER; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GENES, BRCA1; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 84869492811     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0461-1     Document Type: Review

References (57)

1. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71-96
2. Hoskins WJ, Bundy BN, Thigpen JT et al (1992) The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 47(2):159-166
3. Hoskins WJ, McGuire WP, Brady MF et al (1994) The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170(4): 974-979 (discussion 979-980)
4. Eisenkop SM, Friedman RL, Wang HJ (1998) Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 69(2):103-108
5. Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17):3194-3200
6. du Bois A, Neijt JP, Thigpen JT (1999) First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer-a new standard of care? Ann Oncol 10(Suppl 1):35-41
7. Biagi JJ, Eisenhauer EA (2003) Systemic treatment policies in ovarian cancer: the next 10 years. Int J Gynecol Cancer 13(Suppl 2):231-240
8. Neijt JP, Engelholm SA, Tuxen MK (2000) Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18(17):3084-3092
9. Sandercock J, Parmar MK, Torri V et al (2002) First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer 87(8):815-824
10. Greenlee RT, Hill-Harmon MB, Murray T et al (2001) Cancer statistics, 2001. CA Cancer J Clin 51(1):15-36
11. Gore ME, Fryatt I, Wiltshaw E et al (1990) Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36(2):207-211
12. Agarwal R, Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3(7):502-516
13. Sudo T, Ota Y, Kotani S (2001) Activation of Cdh1-dependent APC is required for G1 cell cycle arrest and DNA damageinduced G2 checkpoint in vertebrate cells. EMBO J 20(22):6499-6508
14. Bellacosa A, Kumar CC, Di Cristofano A et al (2005) Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94:29-86
15. Chiang JW, Karlan BY, Cass L et al (2006) BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. Gynecol Oncol 101(3):403-410
16. Chan KY, Ozcelik H, Cheung AN et al (2002) Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res 62(14):4151-4156
17. Martin SA, Lord CJ, Ashworth A(2008) DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 18(1):80-86
18. Farmer H, McCabe N, Lord CJ et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917-921
19. Bryant HE, Schultz N, Thomas HD et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035):913-917
20. Fong PC, Boss DS, Yap TA et al (2009) Inhibition of poly(ADPribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123-134
21. Fong PC, Yap TA, Boss DS et al (2010) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28(15): 2512-2519
22. Turner N, Tutt A, Ashworth A (2004) Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4(10):814-819
23. McCabe N, Turner NC, Lord CJ et al (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66(16):8109-8115
24. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82(1):4-6
25. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57-70
26. Paley PJ, Staskus KA, Gebhard K (1997) Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80(1):98-106
27. Ishigami SI, Arii S, Furutani M (1998) Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 78(10): 1379-1384
28. Mu J, Abe Y, Tsutsui T (1996) Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity. Jpn J Cancer Res 87(9):963-971
29. Hu L, Hofmann J, Zaloudek C et al (2002) Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 161(5):1917-1924
30. Byrne AT, Ross L, Holash J (2003) Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 9(15):5721-5728
31. O'Hanlon LH (2005) Taking down tumors: vascular disrupting agents entering clinical trials. J Natl Cancer Inst 97(17):1244- 1245
32. Siemann DW, Chaplin DJ, Horsman MR (2004) Vascular-targeting therapies for treatment of malignant disease. Cancer 100(12):2491-2499
33. Gaya AM, Rustin GJ (2005) Vascular disrupting agents: a new class of drug in cancer therapy. Clin Oncol (R Coll Radiol) 17(4):277-290
34. Nathan P, Zweifel M, Padhani AR et al (2012) Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res; 18(12): 3428-3439
35. Shaked Y, Ciarrocchi A, Franco M et al (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313(5794):1785-1787
36. McKeage MJ, Fong P, Jeffery M et al (2006) 5,6-Dimethylxanthenone-4- acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res 12(6):1776-1784
37. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489-501
38. Shayesteh L, Lu Y, Kuo WL et al (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21(1):99-102
39. Levine DA, Bogomolniy F, Yee CJ et al (2005) Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 11(8):2875-2878
40. Obata K, Morland SJ, Watson RH et al (1998) Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58(10):2095-2097
41. Cheng JQ, Godwin AK, Bellacosa A et al (1992) AKT2, a putative oncogene encoding a member of a subfamily of proteinserine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 89(19):9267-9271
42. Hu L, Hofmann J, Lu Y, Mills GB et al (2002) Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62(4):1087-1092
43. Yap TA, Garrett MD, Walton MI et al (2008) Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 8(4):393-412
44. Oza AM, Elit L, Tsao MS et al (2011) Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol; 29(24): 3278-3285
45. Slomovitz BM, Lu KH, Johnston T et al (2010) A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 116(23): 5415-5419
46. Singer G, Oldt R 3rd, Cohen Y et al (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95(6):484-486
47. Sieben NL, Macropoulos P, Roemen GM et al (2004) In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 202(3):336-340
48. Singer G, Stohr R, Cope L et al (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and highgrade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29(2):218-224
49. Soda M, Choi YL, Enomoto M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561-566
50. Shaw AT, Yeap BY, Solomon BJ et al (2011) Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12(11):1004-1012
51. Barker SD, Casado E, Gomez-Navarro J et al (2001) An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites. Gynecol Oncol 82(1):57-63
52. Chan JK, Hamilton CA, Anderson EM et al (2007) A novel technique for the enrichment of primary ovarian cancer cells. Am J Obstet Gynecol 197(5):507 e1-5
53. Poveda A, Kaye SB, McCormack R et al (2011) Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecol Oncol 122(3): 567-72
54. Marth C, Kisic J, Kaern J et al (2002) Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis. Cancer 94(3):707-712
55. Kindelberger DW, Lee Y, Miron A et al (2007) Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 31(2):161-169
56. Visvanathan K, Vang R, Shaw P et al (2011) Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. Am J Surg Pathol; 35(12):1766-1775
57. Przybycin CG, Kurman RJ, Ronnett BM (2010) Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 34(10):1407-1416